Flare Therapeutics takes in $82m Series A

Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has raised $82 million in Series A financing.

Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has raised $82 million in Series A financing. Third Rock Ventures led the round with participation from Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management.

Source: Press Release